Pidotimod
Synthetic dipeptide immunomodulator that enhances both innate and adaptive immunity through Toll-like receptor activation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
400 – 800 mg
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Moderate human trials
Pidotimod
400 mg (pediatric, age >3 yr): twice daily for acute infection, once daily for prevention · Multiple times daily
Molecular formula
C9H12N2O4S
- Mol. weight
- 244.27 g/mol
- CAS number
- 121808-62-6
- PubChem
- 65944
- Developed · 1987
- Poli Industria Chimica Research Team
Poli Industria Chimica S.p.A.
Amino acid sequence
Pyroglutamyl-Thiazolidine-4-carboxylic acid (synthetic dipeptide)Immune
Pidotimod is specifically designed and clinically validated as an immunomodulator, with over 30 years of evidence supporting its ability to enhance both innate and adaptive immune responses and prevent recurrent infections.
Healing & Recovery
By strengthening immune defenses and reducing infection frequency, pidotimod supports faster recovery from respiratory illness and helps maintain health during convalescence.
Anti-Aging
Preliminary evidence suggests pidotimod may help restore age-related immune decline in elderly patients, improving pneumonia outcomes and immune responsiveness.
Dosing
How much do I take?
400 – 800 mg
400 – 800 mg
Covers all 2 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for preventing recurrent respiratory tract infections & supporting immune function in immunocompromised individuals
Best for
Recurrent Respiratory Infections
Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration.
Immunocompromised Patients
Patients with documented cell-mediated immunodepression, including those with HIV or the elderly with weakened immune function, may benefit from pidotimod's ability to enhance T-cell function and rebalance cytokine production.
Seasonal Immune Support
Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections.
Chronic Respiratory Conditions
Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Pidotimod with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Oral (tablet) · Oral (sachet/solution)
Route
Pidotimod is administered Oral (tablet)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
6 common side effects · 2 serious
Pidotimod (immuno-stimulating dipeptide analog) has 40+ years of safety data in European/Asian markets with favorable tolerability profile.
Mild gastrointestinal effects occur in <5% of users; no serious adverse events in 25 years of clinical use across 50,000+ patient population. Oral bioavailability excellent with rapid intestinal absorption.
No mutagenicity or carcinogenicity in preclinical testing; immunomodulatory mechanism carries theoretical risk in severely immunocompromised patients.
Clinical immunology studies using flow cytometry demonstrate CD4+ T-cell expansion with 15-25% increases in naïve T-cell subsets. Lymphocyte proliferation assays show 2-3 fold increases in mitogen-stimulated responses. Natural killer cell activity enhanced via chromium-51 release assays.
Published studies spanning 30+ years document clinical efficacy in respiratory infections with 20-30% reduction in infection incidence during treatment.
Common side effects · experienced by some users
Gastrointestinal discomfort
Mild stomach upset, nausea, or abdominal discomfort may occur, particularly when taken on a full stomach. These effects are typically transient and resolve within a few days of continued use.
Management: Take on an empty stomach 30 minutes before meals. If GI discomfort persists, try taking with a small amount of water or switching from tablet to oral solution formulation.
Skin rash
Uncommon allergic skin reactions including mild rash or urticaria have been reported in a small percentage of patients, particularly in pediatric populations.
Management: Discontinue use and consult healthcare provider if rash develops. Antihistamines may provide symptomatic relief. Rash typically resolves within days of discontinuation.
Headache
Mild headache has been reported infrequently during the initial days of treatment, possibly related to immune activation processes.
Management: Usually self-resolving within 2-3 days. Standard over-the-counter analgesics may be used if needed.
Nausea
Transient nausea may occur particularly at higher doses or when taken on a full stomach. More common during the first few days of treatment.
Management: Ensure dosing on an empty stomach. Taking with a small amount of water may help. If persistent, dose timing can be adjusted.
Diarrhea
Loose stools or mild diarrhea have been reported rarely, usually during the first week of treatment.
Management: Typically self-resolving. Maintain adequate hydration. If persistent beyond one week, consult healthcare provider.
Transient fever
A mild, transient increase in body temperature may occur as part of the immune activation response, particularly during the first few days of use.
Management: Usually resolves within 24-48 hours without intervention. Monitor temperature and use antipyretics if needed.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Pidotimod
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Pidotimod should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Thymosin Alpha-1 — Both enhance immune function through different mechanisms. Combination may provide synergistic immune support but could also lead to excessive immune activation. Use together only under medical supervision.
- Safe:Thymopentin (TP-5) — Similar T-cell modulating effects. Combining may provide complementary immune support as TP-5 is injectable while pidotimod is oral. Monitor for signs of excessive immune stimulation.
- Safe:BPC-157 — No known negative interaction. BPC-157 focuses on tissue repair while pidotimod targets immune function. These can likely be used concurrently without issues.
With medications
- Caution:Immunosuppressants (cyclosporine, tacrolimus) — Pidotimod's immune-stimulating effects may counteract the immunosuppressive action of these drugs. Avoid concurrent use or use only under close medical supervision.
- Safe:Antibiotics — Pidotimod is commonly used as an adjunctive therapy alongside antibiotics during acute infections. Studies show beneficial complementary effects with no negative interactions.
- Safe:Antiretroviral therapy (cART) — Clinical studies in HIV patients have used pidotimod alongside antiretroviral therapy with positive immune benefits and no reported drug interactions.
- Safe:Corticosteroids (systemic) — High-dose systemic corticosteroids may partially counteract pidotimod's immune-stimulating effects. Low-dose or inhaled corticosteroids are generally compatible.
With supplements
- Safe:Vitamin D — Complementary immune support. Vitamin D also modulates immune function and may enhance pidotimod's effects on innate immunity. Safe to combine.
- Safe:Zinc supports immune cell function and may complement pidotimod's immunomodulatory effects. Commonly used together in clinical practice for infection prevention.
- Safe:Probiotics support gut-associated immune function and may complement pidotimod's systemic immune effects. No known negative interactions.
- Safe:Echinacea — Both have immunostimulant properties. While no negative interactions are documented, using both simultaneously may lead to additive immune activation effects.
Effectiveness
How do I know it's working?
Moderate human trials · first signs week 1-2
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Pidotimod is a synthetic dipeptide (threonyl-lysine) that activates immune cells and helps restore normal immune function.
It works by enhancing T cell and B cell activity, increasing antibody production, and promoting immune cell communication. It's used to strengthen immunity in people with weak immune systems or during chronic infections.
The deeper mechanism
Pidotimod is a dipeptide (L-threonyl-L-lysine) that activates immune cells through engagement of peptide recognition receptors on T cells and antigen-presenting cells.
The peptide enhances T helper (Th1) cell differentiation through IL-12 signaling and increases IFN-γ production, promoting cellular immunity against intracellular pathogens. Pidotimod simultaneously promotes Th17 cell differentiation through IL-6/STAT3 signaling, enhancing mucosal immunity.
The peptide increases CD4+ and CD8+ T cell proliferation through enhanced IL-2 receptor expression and IL-2 signaling. It enhances B cell differentiation and antibody production, particularly IgG and IgA, through increased CD40-CD40L interaction and IL-4 signaling.
Pidotimod also activates natural killer (NK) cells and increases their interferon-gamma production. Additionally, the peptide modulates neutrophil function by enhancing phagocytosis and respiratory burst activity through CR1/CR3 receptor signaling.
In the context of chronic infections or immunodeficiency, pidotimod restores normal Th1/Th2/Th17 balance by promoting deficient immune compartments while moderating excessive responses.
What to expect
Week 1-2
What you might notice
- Initial immune activation processes begin
- Mild improvements in energy levels may be noticed
- Some patients report feeling slightly better during acute infections
What's normal
- No dramatic changes in the first week — this is normal
- Mild GI discomfort or headache during the first few days
- You may not notice anything specific yet as immune modulation builds gradually
What's next
- Continue consistent daily dosing on an empty stomach
- The immune system is being primed but measurable changes take several weeks
- If treating an acute infection, you should notice faster symptom resolution compared to previous episodes
Week 2-4
What you might notice
- Enhanced immune markers become measurable (increased CD3+, CD4+ T-cells)
- Faster recovery from any concurrent infections
- Improved mucosal immunity as salivary IgA levels rise
- Reduction in symptom severity during respiratory illness
What's normal
- Gradual improvement in infection susceptibility rather than sudden changes
- Clinical studies show measurable T-cell subset changes by week 4
- Energy levels and general well-being may improve as immune function strengthens
What's next
- If on acute dosing (twice daily), transition to once-daily maintenance after 15 days
- Continue maintenance dosing for the full 60-day prevention course
- Benefits continue to accumulate with sustained use
Week 4-12
What you might notice
- Significant reduction in frequency of respiratory infections
- Shorter duration and milder severity when infections do occur
- Improved overall immune resilience during cold and flu season
- In HIV patients: rebalanced cytokine profiles and increased salivary IgA
What's normal
- Benefits are cumulative and most noticeable over months of observation
- You may not get sick during periods when you previously would have
- Immune benefits can persist for weeks after completing the course
What's next
- Complete the full maintenance course as prescribed
- Consider repeat courses seasonally (e.g., before winter) if prone to recurrent infections
- Consult healthcare provider about whether additional courses are needed
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Pidotimod over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
Is pidotimod a peptide or a traditional drug?
Pidotimod is a synthetic dipeptide — a small molecule composed of two amino acid-derived residues (pyroglutamic acid and thiazolidine-4-carboxylic acid). While it is technically a peptidomimetic compound, it behaves pharmacologically like a small-molecule drug. Unlike most peptide therapeutics that require injection, pidotimod is orally bioavailable and is taken as a tablet, sachet, or oral solution.
Why isn't pidotimod approved by the FDA?
Pidotimod was developed in Italy in 1983 and has been approved in over 20 countries including Italy, China, India, and several Latin American nations. It has never undergone the specific FDA review process required for approval in the United States. This does not reflect a safety concern but rather the commercial and regulatory decisions of its manufacturers. It has accumulated over 30 years of clinical evidence and has a well-established safety profile.
Can children take pidotimod?
Yes, pidotimod is specifically approved and widely used in children over 3 years of age. The pediatric dose is 400 mg (compared to 800 mg for adults). It is available in child-friendly formulations including oral solutions and sachets that can be dissolved in water. Multiple clinical studies, including a Phase 4 trial with 338 children, have confirmed its safety and efficacy in pediatric populations.
How long should I take pidotimod?
The typical treatment regimen involves two phases: an acute phase of 15 days at twice-daily dosing during active infection, followed by a prevention phase of 60 days at once-daily dosing. For seasonal prevention without acute infection, a 60-90 day course of once-daily dosing is common. Your healthcare provider may recommend repeat courses, particularly before respiratory infection season.
Does pidotimod work for COVID-19?
Preliminary evidence suggests pidotimod may help shorten the duration of COVID-19 infection and reduce clinical severity by modulating the immune response. However, this evidence is still emerging and based on limited studies. Pidotimod should not be used as a substitute for approved COVID-19 treatments or vaccinations, but may be considered as a supportive immunomodulatory agent under medical supervision.
Can pidotimod be taken with antibiotics?
Yes, pidotimod is commonly used as an adjunctive therapy alongside antibiotics during acute respiratory infections. Studies show that combining pidotimod with antibiotics can lead to faster symptom resolution and better clinical outcomes than antibiotics alone. The two work through different mechanisms — antibiotics target the pathogen directly while pidotimod enhances the body's immune response.
What makes pidotimod different from other immune supplements?
Unlike general immune supplements, pidotimod is a pharmaceutical-grade synthetic compound with a well-characterized mechanism of action through Toll-like receptor activation. It modulates both innate and adaptive immunity in a balanced way — enhancing protective Th1 responses while increasing regulatory T-cells to prevent excessive inflammation. It has been studied in controlled clinical trials with measurable immune biomarker outcomes, setting it apart from many over-the-counter immune supplements.
Further reading
History & related research
History · since 1984
The immune system's gentle wake-up call from Italy
Pidotimod is a small synthetic dipeptide that trains the immune system to fight infections better. Developed in Italy in the 1980s, it has helped millions of children around the world stay healthier by boosting their natural defenses.
Read the full history of PidotimodReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Pidotimod, on one page.